Biogen and Denali Therapeutics said on May 21, 2026 that BIIB122 (DNL151), an oral inhibitor of leucine-rich repeat kinase 2 (LRRK2), did not slow progression of early-stage Parkinson's disease compared with placebo in the phase 2b LUMA study, and that the two companies will discontinue development of the drug in idiopathic Parkinson's. The primary endpoint was time to confirmed worsening on the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined; secondary endpoints also showed no benefit. The trial registration (ClinicalTrials.gov NCT05348785, first posted April 27, 2022, record last updated June 4, 2026) describes LUMA as a multicentre, randomised, double-blind, placebo-controlled phase 2b study in adults aged 30 to 80 with a screening MDS-UPDRS Parts II and III score of 50 or below. NeurologyLive, summarising the registry entry, put the study at 650 participants across 113 sites with completion expected in March 2026; Alzforum reported 648 people enrolled in North America, Asia and Europe, treated for at least 48 weeks and up to 144 weeks.
The biology worked, on the measures the companies reported. Exploratory biomarker endpoints showed more than 90 percent inhibition of peripheral LRRK2 kinase activity (phosphoserine 935), and a cerebrospinal fluid sub-study found a reduction of up to roughly 30 percent in phosphorylated Rab10, a marker of LRRK2 activity. Drug levels in blood and cerebrospinal fluid were sustained across the study, and the companies described BIIB122 as generally well tolerated with an acceptable safety profile. That combination, documented target engagement with no clinical separation, is the recurring problem in neurodegeneration trials: a mechanism can be switched off in the body without the disease course bending.
The numbers so far are topline figures released by the sponsors. No peer-reviewed publication has appeared, no effect sizes or confidence intervals have been made public, and the companies said the data will be presented at a scientific conference. Denali's chief medical officer, Peter Chin, called LUMA a robust test of LRRK2 inhibition in idiopathic Parkinson's while saying there is more to learn about LRRK2 as a target. Denali is continuing, on its own, the smaller phase 2a BEACON study in people who carry a pathogenic LRRK2 variant. The genetic question has had a bumpy path already: Biogen terminated the phase 3 LIGHTHOUSE study in LRRK2-associated Parkinson's in June 2023, citing the length and complexity of that trial, and offered its participants a route into LUMA.
For families concerned with thinking and memory, the important point is what LUMA did not ask. Its primary endpoint measured motor examination and motor aspects of daily living, not cognition, and no dementia or cognitive outcome has been reported from the study. Roughly speaking, this trial tested whether blocking LRRK2 slows motor decline in early Parkinson's; it did not test whether LRRK2 biology contributes to Parkinson's disease dementia or to Lewy body pathology, and the answer to the first question does not settle the second.